PRKAA2 and metabolic dysfunction-associated steatotic liver disease: Our findings highlight miR-200a-5p as a potential target for reducing lipid deposition and ER stress via modulation of AMPK/SERCA2b, offering a new perspective on how metformin ameliorates MASLD.